Panelists discuss the guidance on managing REMS program compliance for bispecific therapies and strategies for educating non-oncology health care providers about cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) toxicities.
Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.
Traci M. Poole, PharmD, BCACP, BCGP, discusses the pathophysiology of respiratory syncytial virus (RSV) and its key complications, identifies high-risk populations for severe RSV infection, and explores best practices for recognizing these patients and ensuring they receive timely vaccination to prevent serious outcomes.
The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.
In this episode of Public Health Matters, Christina Madison discusses the concept of reproductive justice and ensuring Black maternal health efforts are not left behind with Regina Davis Moss of In Our Own Voice.
Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.
Panelists discuss how ursodeoxycholic acid is the first-line treatment for primary biliary cholangitis (PBC), with early initiation being crucial for optimal outcomes and prevention of disease progression.
Panelists discuss how primary biliary cholangitis (PBC) often presents asymptomatically but can be diagnosed through elevated alkaline phosphatase levels, positive antimitochondrial antibodies, and liver biopsy when necessary.
Food insecurity in rural communities can affect hypertension, but pharmacists can mitigate the impact by educating themselves on nutrition options for low-income individuals.
Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.
Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.
Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.
Rural pharmacies and hospitals face unique challenges in maintaining adequate staffing and drug supply inventory to serve patients who often travel long distance.
Panelists discuss how clinical management of CAR T-cell therapy–associated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms.
Panelists discuss understanding institutional protocols for managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) prophylaxis in bispecific antibody therapy, along with criteria for safely selecting patients for outpatient step-up dosing.
AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.
Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.
Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.
Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.
Ira Zackon, MD, explains where future research lies regarding the implementation of bispecific antibodies in community oncology settings.
The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.
Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.
Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.
The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.
Pharmacists are crucial skin care experts and should counsel patients on the importance of adjunct therapies like moisturizers and sunscreen when using certain medications.
The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.
Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.
Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.
